PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-19.76%
Both companies show declining cash positions (-19.76% vs AVXL's -8.53%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-19.76%
Cash + STI yoy ≥ 1.5x AVXL's -8.53%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.43%
Higher Other Current Assets Growth compared to AVXL's zero value, indicating worse performance.
-20.12%
≥ 1.5x AVXL's -8.76%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
13.37%
Higher PP&E (Net) Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.42%
Below half of AVXL's 59.06%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-19.74%
≥ 1.5x AVXL's -8.64%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-6.57%
Less than half of AVXL's 22.09%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
-17.63%
Less than half of AVXL's 22.09%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.63%
Less than half of AVXL's 22.09%. David Dodd sees far fewer liability expansions relative to competitor.
0.13%
Less than half of AVXL's 0.34%. David Dodd sees fewer share issuances vs. competitor.
-2.90%
0.5-0.75x AVXL's -4.97%. Martin Whitman is wary of weaker retention or lower profitability.
-5.63%
Higher AOCI Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-20.37%
≥ 1.5x AVXL's -12.00%. David Dodd sees stronger capital base growth than competitor.
-19.74%
≥ 1.5x AVXL's -8.64%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
19.76%
Above 1.5x AVXL's 8.53%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.